TITLE

SANTHERA ENROLLS LAST PATIENT IN RHODOS STUDY

PUB. DATE
September 2009
SOURCE
Worldwide Biotech;Sep2009, Vol. 21 Issue 9, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the completion of patient recruitment for the six-month Rescue of Hereditary Optic Disease Outpatient Study (RHODOS) of Santhera Pharmaceuticals in 2009. The study will examine the effects of its Catena drug on patients with Leber's hereditary optic neuropathy (LHON). The trials to be done in Munich, Germany, Newcastle, England and Montreal, Quebec is considered the first to test the efficacy of Catena against placebo, and the rationale that Catena may delay vision loss in LHON.
ACCESSION #
43826758

 

Related Articles

  • Good Data have Santhera Eying Approval Filings.  // Bioworld Week;6/21/2010, Vol. 18 Issue 25, p4 

    The article reports that the shares of Santhera Pharmaceuticals Holding AG has earned about 11% due to its plan to file for an approval in 2011 regarding the use of idebenone (Catena) for treating patients with Leber's hereditary optical neurophaty (LHON).

  • Idebenone Falls Short in Second Pivotal Trial.  // Bioworld Week;5/24/2010, Vol. 18 Issue 21, p5 

    The article reports on the effect of the second Phase III trial failure of idebenone on Liestal, Switzerland-based Santhera Pharmaceutical Holdings AG's Friedreich's ataxia program.

  • Research beyond Walls: State University of New York (SUNY) Eye Institute. Brunken, William J.; Knox, Barry E. // Journal of Ophthalmic & Vision Research;Jan2012, Vol. 7 Issue 1, p94 

    The article profiles State University of New York (SUNY) Eye Institute (SEI) and includes information on its mission, history, and organizational structure. It states that SEI is one of the largest ophthalmic research groups in the U.S. that aims to integrate complementary resources of the SUNY...

  • Santhera, Ipsen in $181M Fipamezole Collaboration.  // Bioworld Week;9/13/2010, Vol. 18 Issue 37, p2 

    The article reports that Santhera Pharmaceuticals Holding AG has entered into a 141 million-euro deal with Ipsen Group SA for its Fipamezole Parkinson's disease drug.

  • Santhera Starts Phase III Trial In Friedreich's Ataxia Patients. Shrine, Jim // BioWorld Today;10/1/2007, Vol. 18 Issue 190, p1 

    The article reports that Santhera Pharmaceuticals AG has started its Phase III program for SNT-MC17 drug for ataxia in the U.S. Santhera Pharmaceuticals has reached an agreement with the Food and Drug Administration on a special protocol assessment for the study. The double-blind trials will...

  • Baseling IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Hodge, W. G.; Damji, K. F.; Rock, W.; Buhrmann, R.; Bovell, A. M.; Pan, Y. // British Journal of Ophthalmology;Sep2005, Vol. 89 Issue 9, p1157 

    Background/aims: The efficacy and safety of selective laser trabeculoplasty (SLT) has been found to be equivalent to argon laser trabeculoplasty (ALT). Since SLT produces significantly less disturbance to the trabecular meshwork and is theoretically more repeatable than ALT, it has potential to...

  • The Pulse on Patient Recruitment. Tointon, Ashley // CenterWatch Weekly;11/2/2015, Vol. 19 Issue 43, p6 

    The article discusses aspects of effective strategies to increase patient enrollment/recruitment rates for a clinical trial.

  • Online patient recruitment: Still nascent ater all these years. Redfearn, Suz // CenterWatch Monthly;Jan2017, Vol. 24 Issue 1, p1 

    The article explores the evolution of online patient recruitment and the shortcomings of the early business model for online recruiting companies.

  • Physician research group exploring insert indications. Guttman, Cheryl; Casebeer, J. Charles // Ophthalmology Times;09/15/2000, Vol. 25 Issue 18, p4 

    Reports that Clinical Research and Statistics (CRS), a physician group, is preparing to file Investigational Device Exemptions (IDE) seeking approval to conduct clinical studies of indications for Intacs micro-thin prescription inserts (KeraVision). Some of the clinical trials that are planned;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics